Published in Oncology Business Week, May 3rd, 2009
"The clinical importance of AhR or CYP1B1 overexpression, however, as well as the relationship between AhR and p53 or EGFR in lung carcinomas, remains unclear. Immunohistochemistry for AhR, CYP1B1, EGFR and/or p53 expression was performed on two tissue microarrays containing 152 NSCLC specimens. High levels of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.